Soleno Profitability Milestone And CFO Shift Raise Valuation Questions
“Soleno Therapeutics (NASDAQ: SLNO) achieved a significant profitability milestone in 2025, posting full-year net income of $20.9 million driven by strong U.S. sales of its rare disease therapy VYKAT XR, just nine months after launch. Concurrently, the company announced the retirement of longtime CFO James Mackaness and the appointment of Jennifer Fulk as his successor, … Read more